HURA at a glance
TuHURA Biosciences, Inc./NV (HURA, SEC CIK 1498382) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on September 24, 2026 and Form 4 insider filings as recently as May 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63.
- As of June 30, 2026, 17 institutional investment managers tracked by SignalX reported holding TuHURA Biosciences, Inc./NV (HURA) shares worth $14.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 17 funds
- $14.9M · −2 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 2.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New secured debt risk triggered by Parkview facility: $5.8 million borrowed at 12% interest, collateralized by substantially all company assets
- Most material liquidity risk: $1.0 million cash versus $13.0 million operating cash use during six months ended June 30, 2026
- Financing concentration risk: Parkview facility includes 6% default interest and repayment of 75% of net profits after two profitable quarters
- Clinical execution risk: IFx-2.0 Phase 3 trial and TBS-2025 development increased research and development spending to $11.9 million
- Continuing operating-loss risk: six-month net loss reached $16.7 million with accumulated deficit of $157.9 million
AI summary of the HURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.03: Creation of a Direct Financial Obligation
- $650,000 additional draw under revolving credit facility with Parkview Holdings One LLC
- Total facility availability capped at $50 million, maturing April 21, 2031
Item 2.03: Creation of a Direct Financial Obligation
- $650,000 additional draw under revolving credit facility with Parkview Holdings One LLC
- Total facility capacity up to $50 million, maturing April 21, 2031
Item 5.02: Departure/Appointment of Directors or Principal Officers
- 5,000,000 shares reserved for new-hire inducement awards under Nasdaq Rule 5635(c)(4)
- Equity plan adopted without shareholder approval, enabling recruiting incentives without immediate share issuance
AI summaries of HURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HURA
Don't miss the next HURA filing
- Alerts as it files. A push when HURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HURA, by share count.
- Ask anything. An AI agent that reads every HURA filing and answers with sources.
HURA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bianco James A. | G | May 28, 2026 | 150,000 | - |
| MANUSO JAMES S J | A | Feb 12, 2026 | 156,240 | - |
| Tendler Craig | A | Feb 12, 2026 | 156,240 | - |
| List Alan | A | Feb 12, 2026 | 156,240 | - |
| Ng George K | A | Feb 12, 2026 | 156,240 | - |
| Hoffman Robert E. | A | Feb 12, 2026 | 156,240 | - |
| Bianco James A. | A | Jan 6, 2026 | 610,332 | - |
| Dearborn Dan | A | Jan 6, 2026 | 273,696 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $0 | $0 |
| Net Income | -$29.3M | -$21.7M | -$30.1M |
| Balance Sheet | |||
| Total Assets | $4.4M | $20.0M | $27.4M |
| Equity | - | $14.6M | $20.9M |
| ROE | - | -148.6% | -143.6% |
| Per Share | |||
| EPS | $-2.47 | $-1.21 | $-0.63 |
| Cash Flow | |||
| Operating CF | -$12.0M | -$14.7M | -$27.6M |
| CapEx | $79K | $58K | $76K |
Source: XBRL data in TuHURA Biosciences, Inc./NV (HURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 17 | $14.9M |
| Q1 2026 | 19 | $12.0M |
| Q4 2025 | 18 | $3.8M |
| Q3 2025 | 17 | $11.4M |
| Q2 2025 | 17 | $10.8M |
| Q1 2025 | 8 | $8.0M |
| Q4 2024 | 6 | $3.9M |
- Northern Trust+1.32M (+444%)
- Vanguard Capital Management LLC+193.7K (+9%)
- Morgan Stanley+119.4K (+501%)
- Goldman Sachs Group+61.5K (+88%)
- FMR LLC (Fidelity)+611 (+3%)
- BlackRock−1.76M (-72%)
- State Street Corp−324.5K (-63%)
- AQR Capital Management−182.6K (-30%)
- BNY Mellon−89.9K (-42%)
- Bank of America Corp−35.6K (-46%)
- Millennium Management+454.5K
- Citadel Advisors LLC+232.3K
- Vanguard Portfolio Management LLC−253.6K
- Invesco Ltd−15.2K
- T. Rowe Price Group−13.1K
- Citigroup−1.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 102 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | - | |
| 8-K | May 15, 2026 | - | - | |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | - | - |
| 8-K | Apr 8, 2026 | - | - | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 10-K | Mar 31, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 17, 2026 | - | - | |
| 4 | Feb 17, 2026 | - | - | |
| 4 | Feb 17, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HURA SEC filings: frequently asked questions
Which institutions hold HURA stock?
As of June 30, 2026, the largest TuHURA Biosciences, Inc./NV (HURA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.3 million), Northern Trust ($3.8 million), BlackRock ($1.6 million), Millennium Management ($1.1 million), AQR Capital Management ($993,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HURA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63. The figures come from the XBRL data in the 10-K.
What did HURA report in its latest 8-K?
TuHURA Biosciences, Inc./NV (HURA) filed an 8-K on September 24, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation). $650,000 additional draw under revolving credit facility with Parkview Holdings One LLC.
What are the latest HURA SEC filings?
TuHURA Biosciences, Inc./NV (HURA) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on September 24, 2026 and a Form 4 insider filing on May 29, 2026.
What is HURA's SEC CIK number?
TuHURA Biosciences, Inc./NV (HURA)'s SEC Central Index Key (CIK) is 1498382. EDGAR lists every HURA filing under that number.
Ask anything about HURA
The research agent reads HURA's filings, financials, insider trades and 13F holders, then answers with sources.